Context: Estrogens influence many physiological processes in mammals, including reproduction. Estrogen peripheral actions are mainly mediated through estrogen receptors (ERs) a and b, encoded by ESR1 and ESR2 genes, respectively.
strogens control many physiological processes in mammals, including female reproductive tract development, breast development, reproduction, cardiovascular health, and bone integrity. Estrogen actions are mainly mediated through estrogen receptors (ERs) a and b, which belong to the steroid receptor superfamily (1, 2) and are encoded by ESR1 and ESR2 genes, respectively. These nuclear receptors are known to act as transcriptional regulators through their direct interaction with specific coregulators (3) . To date, only 2 patients with ESR1 mutations have been reported, 1 man (4) and 1 girl (5) . Their clinical phenotypes were in accordance with the Esr1 knockout mouse model previously described (6, 7) . Female Esr1 knockout mice are infertile as a result of anovulation that is associated with multicystic ovaries without corpora lutea and hypoplastic uteri (6) , and have no pubertal mammary gland development (8) . Male Esr1 knockout mice have reduced testis weight and are infertile, with testicular dysmorphogenesis and inactive sperm (6, 9) . Herein, we report cases of familial loss-offunction ESR1 mutation in multiple members of a large Algerian consanguineous family.
Methods

Hormonal evaluation
Hormonal parameters were measured by radioimmunoassay (Immunotech; Beckman Coulter, Marseille, France, for 17b-estradiol, testosterone, and dehydroepiandrosterone sulfate; and Access; Beckman Coulter, Brea, CA, for luteinizing hormone and follicle-stimulating hormone). In the proband, a serum steroid profile was obtained by isotopic dilution-liquid chromatography-tandem mass spectrometry. Plasma concentrations of inhibin A, inhibin B, and anti-Müllerian hormone (AMH) were measured by enzyme immunometric assays (Oxford Bio-Innovation, Kidlington, UK, for inhibins; and Immunotech; Beckman Coulter, for AMH). Sex hormone-binding globulin was measured by IRMA (Cisbio International, Codolet, France).
Genetic and mutational analysis
Informed consent for DNA sequence analysis was obtained. Leukocyte DNA sequence was analyzed with the use of polymerase chain reaction assays for protein-coding exons in ESR1 (GenBank accession number, NM_000125.3). Specific primers used are presented in Supplemental 
Structural and functional studies of the ESR1 mutation
The identified R394H mutation was introduced within the human ER (hER) a ligand-binding domain (Protein Data Bank identification code 1GWR; www.rcsb.org/pdb) using PyMOL software (www.rcsb.org/pdb) (10) . The orientation of the histidine side chain was adjusted using the PyMOL rotamer function. The mutation was inserted by means of site-directed mutagenesis using the QuickChange XLII Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) into a nonmutated ESR1 clone, VP16-ERa (Addgene, Cambridge, MA). Human embryonic kidney 293T (HEK293T) cells were transiently transfected with wildtype (WT) or mutant ESR1 plasmids and a luciferase reporter construct containing 3 estrogen-response elements (EREs), 3xERE-TATA-luc (Addgene). Transfection efficiency was adjusted by cotransfection with a plasmid encoding b-galactosidase regulated by a cytomegalovirus promoter. Transcriptional activity of WT and mutated ERa was also evaluated after treatment of 5 nM with other ER ligands [ethinyl estradiol, clomiphene, diethylstilbestrol (DES), raloxifene, and tamoxifen]. Western blot analysis was also performed, as described previously (11) , to evaluate WT and mutant receptor expression, with an anti-ER antibody (sc-543; Santa Cruz Biotechnology, Santa Cruz, CA).
Results
The proband (family member IV-3), a 25-year-old, 46,XX woman, was referred because of primary amenorrhea. Her clinical characteristics are reported in Table 1 . She had Tanner stage I breast development with mild adipomastia and chest acne ( Fig. 1A ; photograph taken with patient's approval). Pelvic ultrasonography showed enlarged bilateral multicystic ovaries with a small uterus and thin endometrium. Initial hormonal evaluation indicated an extremely high plasma 17b-estradiol level of 9476 pmol/L (normal range for early follicular phase, 120 to 300 pmol/L) that was associated with elevated gonadotropin levels [luteinizing hormone, 24 IU/L (normal range, 2 to 8 IU/L), follicle-stimulating hormone, 13 IU/L (normal range, 2 to 10 IU/L)]. This clinical and biological presentation strongly suggested an estrogen-resistance/insensitivity syndrome. Her thyrotropin level was 2.18 mIU/L (normal range, 0.4 to 4.5). The family's pedigree is presented in Fig. 1B .
The proband's affected 21-year-old sister (IV-5) had no breast development and primary amenorrhea. The proband's affected 46,XY brother (IV-6) had Tanner stage I gonadal development at 18 years of age with a cryptorchid right testis. His left testis volume was hypoplastic to ,1 mL. The 3 affected patients (IV-3, IV-5, and IV-6) presented with marked delayed bone maturation for their chronological age.
The parents (III-5 and III-7) were healthy first cousins. The mother underwent menarche at 15 years of age, and the father achieved puberty at 15 years of age. One of the proband's sisters (IV-4) had normal puberty and underwent menarche at 14 years of age.
Circulating steroid precursors were measured by liquid chromatography-tandem mass spectrometry in the proband (Table 2) . Progesterone, 17-hydroxyprogesterone, testosterone, androstenedione, and dihydrotestosterone were elevated. By contrast, adrenal steroids, including aldosterone, cortisol, dehydroepiandrosterone, 11b-hydroxyandrostenedione, 11-deoxycortisol, and 21-deoxycortisol were within the normal range. The sex hormone-binding globulin level was very low, which suggested the absence of a hepatic effect of estrogen. AMH was normal in the proband, whereas inhibin A and B were significantly elevated. AMH [4.3 pmol/L (normal range, 10 to 364 pmol/L)] and inhibin B [5 pg/mL (normal range, .100 pg/mL)] were low in the brother in conjunction with a low testosterone level.
Genetic analysis revealed a homozygous missense mutation in the fifth coding exon of ESR1 in all affected individuals (Fig. 1C) . The 3 affected family members were homozygous for a change from guanine to adenine at complementary DNA nucleotide 1181 (c.1181G.A), leading to the substitution of histidine for arginine at residue 394 of the ligand-binding domain of ERa (p.Arg394His), a pivotal residue completely conserved among species (Fig. 1D) . Three unaffected related subjects, the proband's parents (III-5 and III-7) and 1 sister (IV-4), were heterozygous for this mutation. The R394H mutation was absent in Exome Variant Server and ExAC databases and predicted to be deleterious according to the SIFT score and PolyPhen-2.
Western blot analysis revealed that both WT and mutant ERa were expressed at similar protein levels in transfected HEK293T cells (Fig. 2A) . Transactivation of an ERE-dependent luciferase reporter gene in transiently transfected HEK293T cells showed a highly reduced sensitivity of R394H ERa mutant to 17b-estradiol stimulation (Fig. 2B) , with an ED50 ;65-fold higher than that of the WT ERa (1300 vs 20 pM, respectively). Potential activating ligands were evaluated for their ability to partially restore estrogen sensitivity. Known ERa ligands bearing (ethinyl estradiol, DES, and raloxifene) or lacking (clomiphene and tamoxifen) hydroxyl groups at the C3 position were tested for their ability to increase transcriptional activity of the R394H mutant. None of the compounds was found to be more efficient than 17b-estradiol in activating the mutant receptor (Fig. 2C) .
The structural consequence of the R394H mutation was determined by substituting histidine for arginine at position 394. In the WT hERa receptor, estradiol is anchored in the binding pocket by 3 hydrogen bonds (Glu353 and Arg394 anchor the C3 hydroxyl groups and His524 anchors the C17; Fig. 2D, upper panel) . His394 in the mutant hERa is unable to properly anchor the estradiol, which is consistent with the altered response of the mutated receptor to its ligand (Fig. 2D, lower panel) .
Discussion
We describe a consanguineous family in which there was a high incidence of pubertal failure. Two female family members and a male family member had markedly elevated serum E2 levels, associated with elevated gonadotropin levels, which were strongly suggestive of an estrogenresistance/insensitivity syndrome. These 3 affected patients were found to have a homozygous missense ESR1 press.endocrine.org/journal/jcemmutation affecting an essential and highly conserved arginine residue in helix H5 of the ERa ligand-binding domain. Interestingly, the arginine residue in ERa is also conserved among other species and in androgen and mineralocorticoid receptors. The mutations of the analog arginine in androgen and mineralocorticoid receptors have been previously associated with androgen-insensitivity syndrome and decreased sensitivity to aldosterone, respectively (12, 13) . Herein, we demonstrate that the R394H ESR1 mutation is deleterious in vitro. The unaffected parents and sister are heterozygous for this mutation, which indicates that this disorder is transmitted as an autosomal recessive trait. Thus, 1 normal allele of ESR1 appears to be sufficient to achieve puberty and fertility in humans as well as in mouse models. Indeed, the heterozygous proband's parents have proven their fertility. The 2 affected sisters had no breast development, illustrating the fact that ERa activity is absolutely required for mammary gland development. Impaired negative estrogen feedback accounts for the elevated gonadotropin levels (7, 14) , and for ovarian cyst formation, which is also described in genetic disorders of steroidogenesis (15, 16) . Ovarian cyst occurrence also requires the intraovarian actions of ERb, the most prevalent estrogen receptor in the ovary (17) . Interestingly, the ovarian phenotype of our patients differed from polycystic ovarian syndrome, given that cysts were larger than accumulating small follicles seen in the majority of patients with polycystic ovarian syndrome. Hormonal analysis in the affected proband revealed high levels of E2 and estrogen precursors, including testosterone, but normal levels of adrenal steroids. These results confirm the ovarian origin of estradiol and testosterone in the proband and her sister. Normal AMH levels suggest that the proband had normal ovarian reserve, whereas elevated levels of inhibin A and B are consistent with gonadotropin stimulation of an otherwise normal ovary. The male patient (IV-6) had a low testosterone level, probably as a result of his cryptorchidism, which was not reported in the sole male with an ESR1 mutation to date (4) . On the basis of his low inhibin B level, it is very likely that spermatogenesis may not occur in our patient. A relationship between cryptorchidism or retractable testes and ESR1 mutation has been reported in male Esr1 knockout mice, consistent with the patient's phenotype (18, 19) .
Estrogens play a critical role in pubertal growth and epiphyseal maturation in both sexes. The first description of a male patient with an ESR1 mutation revealed that estrogen bone effects involved ERa, because this 28-yearold man presented with markedly delayed skeletal maturation and osteoporosis (4) . Likewise, the woman previously reported with an ESR1 mutation also had open epiphyses at the age of 18 years (5). Our observations are in accordance with these previous findings, given that all 3 patients' bone ages were delayed relative to their chronological age. Surprisingly, the proband was of normal height (target height, 155 cm), whereas her sister was tall. The proband presented with intrauterine growth retardation, as opposed to her sister, who had a normal birth weight. Our hypothesis relies on the potential link between birth weight and final height (20) , or the difference between the sisters, with respect to the extent of the phenotypic penetrance of this particular ESR1 mutation.
It cannot be excluded that high levels of circulating estrogens may exert some functional influence through signaling via ERb and G protein-coupled estrogen receptor-1, although genomic or nongenomic estrogendependent effects, respectively (21) (22) (23) , might partially explain the variability in phenotypes. Long-term consequences of high circulating estrogen levels associated with ERa resistance could contribute to cardiovascular disorders and bone alterations. To partially restore estrogen responsiveness in patients with ESR1 mutations, various ER ligands were analyzed (as potential therapeutic options) for their ability to increase transcriptional activity of the mutated receptor. Because of the structural determinant defect in the ligand-binding domain of R394H ERa, we identified pharmacological compounds containing a C3 hydroxyl group that would more stably interact with and thus activate ERa. Although ethinyl estradiol, DES, and raloxifene were more efficient activators than other compounds, none of them was found to be a stronger ERa transactivator than 17b-estradiol. An alternative therapeutic approach to activate this defective ERa receptor would be the use of transcriptional coactivator small molecules that stabilize the ligand/receptor complex to allow activation. This might 
